8-K current report · filed Nov 20, 2026

Erasca, Inc. (ERAS) 8-K Current Report: November 20, 2026

Item 8.01ERAS overview

Short answer

Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on November 20, 2026 reporting Item 8.01 (Other Events). ERAS-0015 showed confirmed ORR of 44% in 2L+ KRAS G12X PDAC, including 69% for KRAS G12D/G12V tumors.

Erasca, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • ERAS-0015 showed confirmed ORR of 44% in 2L+ KRAS G12X PDAC, including 69% for KRAS G12D/G12V tumors
  • Additional activity in NSCLC, 58% ORR across 16-32 mg QD, and BTC, 75% ORR at 32 mg QD
  • Safety remained manageable at 32 mg QD, with 0% discontinuations and 16.7% dose reductions, but one prior Grade 5 pneumonitis death
  • Phase 3 1L pancreatic cancer trial accelerated to the first half of 2027, materially increasing near-term execution and funding needs
  • ERAS-4001 showed favorable preliminary safety and activity, supporting a planned 2027 combination trial with ERAS-0015

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Erasca, Inc. 8-K filings

Get the next ERAS 8-K as it lands

Follow ERAS for push alerts, or ask the research agent what this filing means.